- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: SWIFT: Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV (clinicaltrials.gov) - Jul 7, 2022 P=N/A, N=80, Recruiting, In this post-hoc analysis with modest subgroup numbers, once-weekly semaglutide appeared consistently more efficacious versus comparators across age and BMI subgroups in Japanese patients, with a similar safety profile. Not yet recruiting --> Recruiting
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical, Journal: High-Dose Once-Weekly Semaglutide: A New Option for Obesity Management. (Pubmed Central) - Jun 29, 2022 Most importantly, the results were obtained after three months of treatment and persisted thereafter. High-dose once-weekly semaglutide can significantly reduce weight, and although gastrointestinal adverse effects were common, it is generally well tolerated.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Targeting cardiovascular risk factors with GLP-1 RAs in people with obesity (Stockholm) - Jun 27, 2022 - Abstract #ESC2022ESC_5249; Urgent need remains for larger studies focussing on liver biopsy. Sponsored by Novo Nordisk •To recognize obesity as a chronic disease and establish its relation to CV risk factors •To present the improvements in cardiometabolic risk factors in PwO using GLP-1 RAs from clinical evidence •To explore future perspectives of semaglutide 2.4 mg in CV space Disclaimer: Semaglutide 2.4 mg once weekly is being investigated in subjects to improve CV risk and with heart failure with preserved ejection fraction
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity. (Pubmed Central) - Jun 25, 2022 Sponsored by Novo Nordisk •To recognize obesity as a chronic disease and establish its relation to CV risk factors •To present the improvements in cardiometabolic risk factors in PwO using GLP-1 RAs from clinical evidence •To explore future perspectives of semaglutide 2.4 mg in CV space Disclaimer: Semaglutide 2.4 mg once weekly is being investigated in subjects to improve CV risk and with heart failure with preserved ejection fraction Semaglutide offers adults with obesity or overweight a new treatment in conjunction with a weight management program consisting of reduced calorie diet and increased physical activity.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed: Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis (clinicaltrials.gov) - Jun 22, 2022 P3, N=375, Active, not recruiting, At a willingness-to-pay threshold of CAD50,000 per QALY gained, once-weekly semaglutide 1 mg was cost-effective over 40 years versus once-daily canagliflozin 300 mg for the treatment of T2DM in patients failing to maintain glycemic control with metformin alone. Recruiting --> Active, not recruiting
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Discovery of once-weekly, peptide-based selective GLP-1 and cholecystokinin 2 receptors co-agonists. (Pubmed Central) - Jun 9, 2022 In a 21-day study in DIO mice, once-weekly administration of 3d and 3h significantly induced body weight loss, improved glucose tolerance, and normalized lipid metabolism, to a greater extent than semaglutide. The current study showed the antidiabetic and antiobesity potentials of GLP-1R/CCK-2R dual agonists that warrant further investigation.
|